Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The m

Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 40.9% to $0.16 during Thursday's pre-

June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meet

Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market s

June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Priv

June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&

June 17, 2026 Biodexa Pharmaceuticals PLC Postponement and Re-scheduling of Annual General Meeting B

May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a cli

U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market

GAME stock rose 52.3% in pre-market trading after reporting positive EBITDA and financials. Other ga

SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from

April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Su

March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidi

March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strat

Shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ: BDRX) are set to reverse split on the

March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pha

Radiopharm Theranostics (NASDAQ: RADX - Get Free Report) and Biodexa Pharmaceuticals (NASDAQ: BDRX -

March 9, 2026 Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Gr

MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stro

February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ: BDRX - Get Free Report) was the recipient of a

January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financ

Biodexa Pharmaceuticals (NASDAQ: BDRX - Get Free Report) and Cadrenal Therapeutics (NASDAQ: CVKD - G

December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals P

December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta

November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in

Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the co